Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics ( (AU:ATH) ) has provided an announcement.
Alterity Therapeutics announced that its CEO, David Stamler, will present a corporate update at the Biotech Showcase. This presentation highlights the company’s progress, particularly the positive data from its ATH434 trials for Multiple System Atrophy, potentially strengthening its position in the neurodegenerative disease treatment market.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Parkinson’s disease and related disorders. The company has demonstrated efficacy in its lead asset, ATH434, through clinical trials and is based in Melbourne, Australia, and San Francisco, USA.
YTD Price Performance: 40.0%
Average Trading Volume: 13,444,263
Technical Sentiment Signal: Sell
Current Market Cap: A$128.9M
Learn more about ATH stock on TipRanks’ Stock Analysis page.